SEARCH:   Advanced

Blood, 15 November 2007, Vol. 110, No. 10, pp. 3499-3506. Prepublished online as a Blood First Edition Paper on July 30, 2007; DOI 10.1182/blood-2007-02-069716. This Article Full Text (PDF) All Versions of this Article: blood-2007-02-069716v1 110/10/3499    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nauta, A. J. Articles by Fibbe, W. E. Search for Related Content PubMed PubMed Citation Articles by Nauta, A. J. Articles by Fibbe, W. E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 6, 2007 Accepted July 9, 2007 Immunomodulatory properties of mesenchymal stromal cells Alma J. Nauta and Willem E. Fibbe* Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands * Corresponding author; email: w.e.fibbe{at}lumc.nl. Mesenchymal stem cells (MSCs) are multipotential nonhematopoietic progenitor cells capable of differentiating into multiple lineages of the mesenchyme. MSCs have emerged as a promising therapeutic modality for tissue regeneration and repair. Further clinical interest has been raised by the observation that MSCs are immunoprivileged and, more importantly, display immunomodulatory capacities. Although the mechanism underlying the immunosuppressive effects of MSCs have not been clearly defined, their immunosuppressive properties have already been exploited in the clinical setting. The aim of this review is to critically discuss the immunogenicity and immunomodulatory properties of MSCs, both in-vitro and in-vivo, the possible underlying mechanisms, the potential clinical use of MSCs as modulators of immune responses in-vivo, and to indicate clinical safety concerns and recommendations for future research. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: O. Jones, A Lacson, X Zeng, J. Jones, K Katti, R. Cahill, and A. Ahmed Long-term follow-up after non-myeloablative transplant of bone and marrow in BXSB mice Lupus, August 1, 2009; 18(9): 813 - 821. [Abstract] [PDF] T. M. Brusko Mesenchymal Stem Cells: A Potential Border Patrol for Transplanted Islets? Diabetes, August 1, 2009; 58(8): 1728 - 1729. [Full Text] [PDF] Y. Ding, D. Xu, G. Feng, A. Bushell, R. J. Muschel, and K. J. Wood Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9 Diabetes, August 1, 2009; 58(8): 1797 - 1806. [Abstract] [Full Text] [PDF] R. Wehner, D. Wehrum, M. Bornhauser, S. Zhao, K. Schakel, M. P. Bachmann, U. Platzbecker, G. Ehninger, E. P. Rieber, and M. Schmitz Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells Haematologica, August 1, 2009; 94(8): 1151 - 1156. [Abstract] [Full Text] [PDF] M. A. Matthay Mesenchymally "stemming" angiogenesis Blood, April 30, 2009; 113(18): 4131 - 4132. [Full Text] [PDF] H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase Cancer Res., April 1, 2009; 69(7): 3228 - 3237. [Abstract] [Full Text] [PDF] Y. Huang, P. Johnston, B. Zhang, A. Zakari, T. Chowdhry, R. R. Smith, E. Marban, H. Rabb, and K. L. Womer Kidney-Derived Stromal Cells Modulate Dendritic and T Cell Responses J. Am. Soc. Nephrol., April 1, 2009; 20(4): 831 - 841. [Abstract] [Full Text] [PDF] D. C. Vela, G. V. Silva, J. A.R. Assad, A. L.S. Sousa, S. Coulter, M. R. Fernandes, E. C. Perin, J. T. Willerson, and L. M. Buja Histopathological Study of Healing After Allogenic Mesenchymal Stem Cell Delivery in Myocardial Infarction in Dogs J. Histochem. Cytochem., February 1, 2009; 57(2): 167 - 176. [Abstract] [Full Text] [PDF] M. Rafei, J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M.-N. Boivin, K. Doody, M. Tremblay, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction Blood, December 15, 2008; 112(13): 4991 - 4998. [Abstract] [Full Text] [PDF] J. S. Burchfield, M. Iwasaki, M. Koyanagi, C. Urbich, N. Rosenthal, A. M. Zeiher, and S. Dimmeler Interleukin-10 From Transplanted Bone Marrow Mononuclear Cells Contributes to Cardiac Protection After Myocardial Infarction Circ. Res., July 18, 2008; 103(2): 203 - 211. [Abstract] [Full Text] [PDF] D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667. [Full Text] [PDF] R. Atoui, D. Shum-Tim, and R. C.J. Chiu Myocardial Regenerative Therapy: Immunologic Basis for the Potential "Universal Donor Cells" Ann. Thorac. Surg., July 1, 2008; 86(1): 327 - 334. [Abstract] [Full Text] [PDF] R. Abdi, P. Fiorina, C. N. Adra, M. Atkinson, and M. H. Sayegh Immunomodulation by Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Type 1 Diabetes Diabetes, July 1, 2008; 57(7): 1759 - 1767. [Abstract] [Full Text] [PDF] T. C. Lund, J. Tolar, and P. J. Orchard Granulocyte colony-stimulating factor mobilized CFU-F can be found in the peripheral blood but have limited expansion potential Haematologica, June 1, 2008; 93(6): 908 - 912. [Abstract] [Full Text] [PDF] R. C.J. Chiu The Challenge of "Tending the Bridge" Ann. Thorac. Surg., April 1, 2008; 85(4): 1149 - 1150. [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020